Matt O'Brien Analyst PerformanceSr. Research Analyst at Piper SandlerMatt O'Brien is a stock analyst at Piper Sandler focused in the medical sector, covering 26 publicly traded companies. Over the past year, Matt O'Brien has issued 38 stock ratings, including buy and hold recommendations. While full access to Matt O'Brien's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Matt O'Brien's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings66 Last 4 YearsBuy Recommendations77.78% 49 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution63RatingsDistribution of strong buy, buy, hold, and sell ratings by Matt O'Brien.RatingPercentageCount Strong Buy0.0%0 ratings Buy77.8%49 ratings Hold22.2%14 ratings Sell0.0%0 ratingsOut of 63 total stock ratings issued by Matt O'Brien at Piper Sandler, the majority (77.8%) have been Buy recommendations, followed by 22.2% Hold.Best & Worst CallsBest Call000.0%GMEDMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%CVRXFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ65.4% of companies on NASDAQ17 companiesNYSE34.6% of companies on NYSE9 companiesMatt O'Brien, an analyst at Piper Sandler, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Matt O'Brien of Piper Sandler specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED INSTRUMENTS15 companies57.7%MED PRODUCTS5 companies19.2%SURGICAL, MEDICAL, AND DENTAL INSTRUMENTS AND SUPPLIES2 companies7.7%MED - BIOMED/GENE2 companies7.7%MED/DENTAL - SUPP2 companies7.7% About Matt O'BrienMatt O'Brien is a senior research analyst and managing director at Piper Sandler covering medical technology and devices. Before joining Piper Sandler in 2014, O'Brien covered medical technology at William Blair for 10 years. Additional work experience includes five years of middle-market investment banking financial advisory work and two years at a healthcare manufacturing and distribution company. O'Brien holds an MBA from the University of Chicago Booth School of Management and a Bachelor of Science from DePaul University in finance.Follow on LinkedIn Matt O'Brien's Ratings History at Piper Sandler Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsSIShoulder Innovations5/8/2026Reiterated Rating$12.76$19.00Overweight$0.0000.00% ROIATECAlphatec5/6/2026Reiterated Rating$10.23$14.00Overweight$0.0000.00% ROITMDXTransMedics Group5/6/2026Lower Price Target$73.07$120.00Overweight$0.0000.00% ROIITGRInteger5/1/2026Reiterated Rating$85.09$97.00Overweight$0.0000.00% ROIPRCTPROCEPT BioRobotics4/30/2026Reiterated Rating$21.71$35.00Overweight$0.0000.00% ROIADGMAdagio Medical4/14/2026Initiated Coverage$1.33$3.00Overweight$0.0000.00% ROIADGMAdagio Medical4/14/2026Initiated Coverage$1.63$3.00Overweight$0.0000.00% ROIMDTMedtronic4/1/2026Lower Price Target$86.25$91.00Neutral$0.0000.00% ROIMMEDMiniMed Group3/31/2026Initiated Coverage$14.35$16.00Neutral$0.0000.00% ROITELATELA Bio3/25/2026Lower Price Target$0.70$1.00Neutral$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. TNDMTandem Diabetes Care3/17/2026Upgrade$21.91$33.00Overweight$0.0000.00% ROICNMDCONMED3/17/2026Downgrade$37.44$39.00Neutral$0.0000.00% ROIPRCTPROCEPT BioRobotics2/26/2026Lower Price Target$21.66$28.00Overweight$0.0000.00% ROIATECAlphatec2/25/2026Reiterated Rating$13.44Overweight$0.0000.00% ROITMDXTransMedics Group2/25/2026Boost Price Target$137.22$160.00Overweight$0.0000.00% ROITNDMTandem Diabetes Care2/20/2026Reiterated Rating$18.52$21.00Neutral$0.0000.00% ROIDXCMDexCom2/5/2026Reiterated Rating$70.55Overweight$0.0000.00% ROIPENPenumbra1/15/2026Downgrade$351.68$374.00Hold$0.0000.00% ROIGMEDGlobus Medical1/8/2026Reiterated Rating$90.58$115.00Overweight$0.0000.00% ROISGHTSight Sciences1/5/2026Set Price Target$7.48$9.00$0.0000.00% ROITMDXTransMedics Group12/22/2025Reiterated Rating$132.89Overweight$0.0000.00% ROIKMTSKestra Medical Technologies12/12/2025Boost Price Target$24.91$30.00Overweight$0.0000.00% ROITELATELA Bio11/14/2025Reiterated Rating$1.11$1.25Neutral$0.0000.00% ROISIShoulder Innovations11/12/2025Reiterated Rating$14.94$18.00Overweight$0.0000.00% ROICNMDCONMED11/6/2025Lower Price Target$41.95$55.00Overweight$0.0000.00% ROIPRCTPROCEPT BioRobotics11/5/2025Reiterated Rating$32.53$50.00Overweight$0.0000.00% ROIDXCMDexCom10/31/2025Set Price Target$56.91$75.00Buy$0.0000.00% ROITMDXTransMedics Group10/30/2025Lower Price Target$136.30$140.00Overweight$0.0000.00% ROIBBNXBeta Bionics10/29/2025Reiterated Rating$28.86$32.00Overweight$0.0000.00% ROIITGRInteger10/24/2025Lower Price Target$71.94$82.00Overweight$0.0000.00% ROIDXCMDexCom10/21/2025Set Price Target$68.92$100.00Overweight$0.0000.00% ROIKIDSOrthoPediatrics10/10/2025Lower Price Target$17.95$22.00Overweight$0.0000.00% ROISIShoulder Innovations8/25/2025Initiated Coverage$12.63$18.00Overweight$0.0000.00% ROITNDMTandem Diabetes Care8/7/2025Downgrade$14.39$14.00Neutral$0.0000.00% ROIPRCTPROCEPT BioRobotics8/7/2025Lower Price Target$39.01$55.00Overweight$0.0000.00% ROIDXCMDexCom7/31/2025Boost Price Target$84.46$100.00Overweight$0.0000.00% ROICNMDCONMED7/31/2025Lower Price Target$51.07$68.00Overweight$0.0000.00% ROITMDXTransMedics Group6/4/2025Reiterated Rating$130.38$145.00Overweight$0.0000.00% ROITMDXTransMedics Group5/9/2025Reiterated Rating$114.25$125.00Overweight$00.0000.00% ROIGMEDGlobus Medical5/9/2025Lower Price Target$55.18$80.00Overweight$00.0000.00% ROITrump Just Executed a Bloodless Coup & Nobody Noticed (Ad)For the first time in history, a sitting U.S. president has effectively positioned himself to control the Federal Reserve - and it may begin as soon as May 15th. A handful of little-known stocks could be positioned for dramatic gains of 1,000% or more over the next 12-24 months as this power shift plays out.Get three stock picks and one free ticker symbol right nowCVRXCVRx5/9/2025Lower Price Target$5.08$12.00Overweight$0.0000.00% ROIKIDSOrthoPediatrics5/8/2025Lower Price Target$22.99$30.00Overweight$00.0000.00% ROIATECAlphatec5/2/2025Reiterated Rating$11.58$15.00Overweight$00.0000.00% ROIDXCMDexCom5/2/2025Lower Price Target$81.70$90.00Overweight$00.0000.00% ROITNDMTandem Diabetes Care5/1/2025Lower Price Target$19.61$30.00Overweight$00.0000.00% ROITMDXTransMedics Group4/29/2025Reiterated Rating$90.00$105.00Overweight$000.0000.00% ROIGKOSGlaukos4/15/2025Lower Price Target$93.22$165.00Overweight$000.0000.00% ROIKMTSKestra Medical Technologies3/31/2025Initiated Coverage$23.43$27.00Overweight$00.0000.00% ROITELATELA Bio3/21/2025Downgrade$2.34$2.00Neutral$0.0000.00% ROISGHTSight Sciences3/6/2025Lower Price Target$2.21$3.50Neutral$0.0000.00% ROITFXTeleflex2/28/2025Reiterated Rating$138.99$140.00Neutral$000.0000.00% ROIATECAlphatec2/27/2025Boost Price Target$11.06$13.00Overweight$00.0000.00% ROIBBNXBeta Bionics2/24/2025Initiated Coverage$20.57$26.00Overweight$00.0000.00% ROIPODDInsulet2/21/2025Boost Price Target$288.29$310.00Overweight$000.0000.00% ROIPENPenumbra2/19/2025Reiterated Rating$270.99$330.00Overweight$000.0000.00% ROIATRCAtriCure2/13/2025Boost Price Target$39.55$50.00Overweight$00.0000.00% ROISTAASTAAR Surgical2/12/2025Lower Price Target$14.94$16.00Neutral$00.0000.00% ROICVRXCVRx2/5/2025Boost Price Target$14.89$20.00Overweight$0.0000.00% ROIBSXBoston Scientific2/3/2025Boost Price Target$103.00$115.00Overweight$00.0000.00% ROIGKOSGlaukos1/27/2025Reiterated Rating$160.49$180.00Overweight$000.0000.00% ROIHUMAHumacyte10/18/2024Set Price Target$5.09$6.00Neutral$0.0000.00% ROIGKOSGlaukos10/17/2024Set Price Target$132.97$140.00$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageUBS GroupCitigroupBarclaysWells Fargo & CompanyMorgan StanleyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James FinancialBMO Capital Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
